C014CIP/DIV1/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned

Group Art Unit: 1641

Applicants : Michael J. Yellin et al.

Serial No. : 09/343,001

Filed : June 29, 1999

FOR : THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM

(CD40-L) MONOCLONAL ANTIBODY 5C8 FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASE

January 18, 2000 New York, New York

Hon. Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicants make of record, the following documents, copies of which are submitted herewith:

PCT Patent Applications

PCT WO 98/30240, published July 16, 1998. PCT WO 98/30241, published July 16, 1998.

OTHER REFERENCES

Press Release from Biogen website (www.prnewswire.com), "Biogen Says it Has Halted Several Trials of Anti-CD40 Ligand Monoclonal Antibody", October 21, 1999.

Press Release from Biogen website (www.prnewswire.com), "Biogen Says it Has Stopped Ongoing Trials of Anti-CD40 Ligand Monoclonal Antibody", November 2, 1999.

Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241).

January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241).

Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240).

January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240).

For the Examiner's convenience, the above-mentioned documents are listed on the accompanying Form PTO-1449.

Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the continued examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449, duly initialed by the Examiner, be forwarded to the undersigned with the next communication.

Since this Statement is submitted more than three months from the application filing date and after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a Notice of Allowance under 37 C.F.R. § 1.311, the Commissioner is hereby authorized to charge payment of the \$240.00 fee required pursuant to 37 C.F.R. § 1.17(p) to Deposit Account No. 06-1075*. The Commissioner is hereby authorized to charge payment of any additional fees required in connection with this Information Disclosure Statement to Deposit Account

I hereby Certify that this Certebromioned is being Deposited with the U.S. Poly 1 Carolina to First Class this is a factor of the Edward Community of

Signature of Person Signing

Res

bectfully submitted,

Margaret A. Pierri (Reg. No. 30,709)

Attorney for Applicants

Stanley D. Liang (Reg. No. 43,753)

Agent for Applicants

c/o FISH & NEAVE

1251 Avenue of the Americas New York, New York 10020-1104

Tel.: (212) 596-9000

^{*} See accompanying Transmittal Letter, filed concurrently herewith in duplicate.

FORM PTO-1449 U.S. DEPARTMENT OF COMMINE PATENT AND TRADEMARK OF		055	ATTY. DOCI C014CIP/DIV	SERIAL NO. 09/343,001			
(📝 🔪 INFORMATION DISCI	OSURE 1/) ()	APPLICANT Michael J. Y			
O 121 2 4 200	STATEMENT BY APP	PLICANT	JAN 2 4 2000	FILING DATE June 29, 1999		GROUP 1641	
FOREIGN PARAMETER							
EXAMINER	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL						YES	NO_
	WO 98/30240	7/16/98	PCT	A61K	39/395		
	WO 98/30241	7/16/98	PCT	A61K	39/395		
	<u> </u>		<u> </u>				
				 			
			 	 			
		<u> </u>		ļ			
			<u> </u>				
				 			-
		<u> </u>	 	 			
					 		<u> </u>
		 		 			
			 				
	-		 	 			
				 			

EXAMINER

DATE CONSIDERED

F	0	R	M	1 6	ÞΤ	0	_1	44	la
	v	г	IV	ır		v	- 1		13

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFF

ATTY. DOCKET NO. C014CIP/DIV1/US

SERIAL NO. 09/343,001

INFORMATION DISCLOSURE

APPLICANT Michael J. Yellin et al. **FILING DATE**

June 29, 1999

GROUP 1641

JAN 2 4 2000 STATEMENT BY APPLICANT

OTHER DOCUMENTS (Including Authoritie, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL							
	Press Release from Biogen website (www.prnewswire.com), "Biogen Says it Has Halted Several Trials of Anti-CD40 Ligand Monoclonal Antibody", October 21, 1999.						
	Press Release from Biogen website (www.prnewswire.com), "Biogen Says it Has Stopped Ongoing Trials of Anti-CD40 Ligand Monoclonal Antibody", November 2, 1999.						
	Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241). January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241).						
	Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240).						
	January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240).						
<u> </u>							

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.